More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$273328755
EPS
-1.04
P/E ratio
--
Price to sales
1.94
Dividend yield
--
Beta
1.003454
Previous close
$4.03
Today's open
$4.04
Day's range
$3.96 - $4.10
52 week range
$2.08 - $4.58
show more
CEO
Carrie Eglinton Manner
Employees
501
Headquarters
Bethlehem, PA
Exchange
Nasdaq Global Select
Shares outstanding
68848553
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th
BETHLEHEM, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. It will hold its quarterly conference call to discuss the results beginning at 5 p.m. Eastern Time on that day.
GlobeNewsWire • Jul 22, 2026

OraSure Receives Emergency Use Authorization for Second Generation Ebola Test
The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients. The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients.
GlobeNewsWire • Jul 21, 2026

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
BETHLEHEM, Pa., June 11, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions today announced U.S. Food and Drug Administration (FDA) clearance of its Colli-Pee™•Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche's tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) and run on Roche's cobas® 5800, 6800, and 8800 molecular diagnostic systems.
GlobeNewsWire • Jun 11, 2026

OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript
OraSure Technologies, Inc. (OSUR) Q1 2026 Earnings Call Transcript
Seeking Alpha • May 7, 2026

OraSure Announces First Quarter 2026 Financial Results
BETHLEHEM, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended March 31, 2026.
GlobeNewsWire • May 6, 2026

OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certain business developments for 5 p.m. ET on May 6, 2026.
GlobeNewsWire • Apr 22, 2026

OraSure Technologies Appoints John D. Bertrand to its Board of Directors
Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the appointment of John D.
GlobeNewsWire • Apr 17, 2026

Exclusive: Altai Capital presses OraSure to sell and give it board seats, letter says
Activist investor Altai Capital Management called on OraSure Technologies to explore a sale, saying the medical device maker could fetch double its current share price, according to a letter seen by Reuters.
Reuters • Mar 17, 2026

OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital
Company Has Demonstrated Momentum on Transformation Strategy with Significant Regulatory and Commercial Milestones Approaching in 2026 Highlights Extensive Engagement with Altai Altai Has Rejected All Settlement Proposals and Is Singularly Focused on Securing Board Representation for Its Founder to Force an Ill-Timed Sale Process BETHLEHEM, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and the “Company”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today issued the following statement in response to Altai Capital's March 17, 2026, letter: OraSure's Board and management team are steadfast in our commitment to driving value and acting in the best interests of all shareholders through disciplined execution and rigorous oversight.
GlobeNewsWire • Mar 17, 2026

Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance
LOS ANGELES--(BUSINESS WIRE)--Altai Capital Management, L.P. ("Altai"), one of the largest shareholders and the beneficial owners of approximately 5% of the outstanding common stock of OraSure Technologies, Inc. (“OraSure” or the “Company”) (NASDAQ: OSUR), today announced that it has delivered a letter to the OraSure Board of Directors (the “Board”) outlining a five-pillar case for why change is necessary to preserve and deliver value for its investors. In the letter, Altai calls on the OraSure.
Business Wire • Mar 17, 2026

¹ Disclosures

Open an M1 investment account to buy and sell OraSure Technologies Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.